AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Voyager Therapeutics, Inc.
Video analysis: VYGR
All videosNo video analysis for this stock yet. Request one from our team.
News: VYGR
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR
BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 5,172,063 shares of the company's stock, valued at approximately $18,102,000. BlackRock Inc. owned about 8.56% of Voyager Therapeutics at the end of the
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m.
Dimensional Fund Advisors LP Sells 208,931 Shares of Voyager Therapeutics, Inc. $VYGR
Dimensional Fund Advisors LP decreased its position in Voyager Therapeutics, Inc. (NASDAQ: VYGR) by 19.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 875,568 shares of the company's stock after selling 208,931 shares during the period. Dimensional Fund Advisors LP owned
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul.
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.
Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year.
